TWOEquity · Weekly research terminal

6847

Puriblood Medical Co., Ltd.

TW Healthcare Diagnostics & Research

Latest week
14 Aug 2026
Weekly close
79.30 TWD
Fair value
91.94 TWD
Next-week expectancy
Negative 34.37%
Sharemaestro
Weekly Chart Pack Completed weekly market data · Independent research

TWO · Equity · Taiwan

6847

Puriblood Medical Co., Ltd.

Healthcare Diagnostics & Research

Puriblood Medical Co., Ltd. engages in the research and development of blood purification-related medical devices in Taiwan and internationally. The company offers leukoreduction, cell separation, and P-Tex, an anti-fouling technology, which is composed by bio-inspired molecular formula. It is also involved in animal blood transfusion. Puriblood Medical Co., Ltd. was incorporated in 2015 and is based in Hsinchu City, Taiwan.

Last updated
14 Aug 2026
Exchange
Taipei Exchange · TWO
Sector
Healthcare
Industry
Diagnostics & Research
Currency
TWD
Market capitalisation
1,128,439,040
Fair value reference
91.94
Next-week expectancy
Negative · 34.37%

Over the latest 12 completed weeks ending 2026-08-14, 6847 rose 4.07%, moving from 76.20 to 79.30. The latest weekly close is above the Trend Line and below Fair Value. Trend Signal is active on the latest week and was active in 6 of the last 12 weeks. Relative Strength is -21.59 and has improved across the 12-week window. Market Dynamics is 0.50 on the latest week. Next-week expectancy is negative at 34.37% based on similar historical setup states.

Week Ending
14 Aug 2026
Latest Close
79.30
12-Week Change
4.07%
Trend Signal
Active
Next-Week Expectancy
Negative 34.37%
Signal Weeks
6 of 12

Weekly Price

Weekly Close Trend Line Fair Value Activity Lines

Chart Panels

Choose up to 5 panels. Drag panel headers to reorder.

Chart Summary

Key Points

Week Ending
14 Aug 2026
Latest Close
79.30
12-Week Change
4.07%
Trend Signal
Active
Next-Week Expectancy
Negative 34.37%
Signal Weeks
6 of 12
Vs Trend Line
Above
Vs Fair Value
Below
Relative Strength
-21.59
Market Dynamics
0.50

Over the latest 12 completed weeks ending 2026-08-14, 6847 rose 4.07%, moving from 76.20 to 79.30. The latest weekly close is above the Trend Line and below Fair Value. Trend Signal is active on the latest week and was active in 6 of the last 12 weeks. Relative Strength is -21.59 and has improved across the 12-week window. Market Dynamics is 0.50 on the latest week. Next-week expectancy is negative at 34.37% based on similar historical setup states.

Industry Peers

Taiwan equities in Diagnostics & Research

Stock Exchange Week Open High Low Close Change
6939 TFBS Bioscience Inc. TWO 14 Aug 2026 19.50 20.00 18.70 19.65 0.77%
7595 Pharmigene, Inc. TWO 14 Aug 2026 7.20 7.36 6.90 7.25 0.69%
1784 BIONET Corp. TWO 14 Aug 2026 60.20 62.90 60.20 60.60 0.66%
4160 Genetics Generation Advancement Corp. TWO 14 Aug 2026 40.15 41.00 39.40 39.80 -0.87%
6615 Sofiva Genomics Co.,Ltd. TWO 14 Aug 2026 34.20 34.60 33.45 33.75 -1.32%
4153 DIVA Laboratories, Ltd. TWO 14 Aug 2026 33.45 33.45 32.40 33.00 -1.35%
6645 Kim Forest Enterprise Co., Ltd. TAI 14 Aug 2026 13.55 13.60 13.10 13.25 -2.21%
6661 Welgene Biotech Co.,Ltd. TWO 14 Aug 2026 17.60 17.60 16.00 16.75 -4.83%

Next-week expectancy

Next-week expectancy is a short-term historical read. It compares the latest completed-week setup with broadly similar past setups and asks whether the following week tended to close higher or lower.

It is not a trend call, a price target, or a guarantee. A positive read can appear while price is below trend or activity pressure is weak, because it is measuring short-term follow-through odds for the current setup state.

Use it as one context layer beside Trend Line, Relative Strength, Market Dynamics, Fair Value, and the visible price structure.

Evidence context